Schizophrenic Patients in Integrated Care

CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study

The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month

Inclusion Criteria:

• Patients with baseline SWN-K <=70
• Provision of signed informed consent
• Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points

Exclusion Criteria:

• Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS
• Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation
• Patients who pose an imminent risk of suicide or danger to self or others